← Eichor
Condition: Relapsed Pediatric Aml Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Relapsed Pediatric Aml

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Phase 1 · 31 location(s) · Therapeutic Advances in Childhood Leukemia Consortium · NCT05476770Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
Phase 2 · 12 location(s) · Children's Hospital of Soochow University · NCT06316960Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Phase N/A · 5 location(s) · Children's Hospital Medical Center, Cincinnati · NCT06131801A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS
Phase 1 · 19 location(s) · Children's Oncology Group · NCT06247787Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Predict
Phase N/A · 2 location(s) · Peking University People's Hospital · NCT06452732The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia T
Phase 1/Phase 2 · 183 location(s) · PedAL BCU, LLC · NCT04726241FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myel
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06609928Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Phase 1 · 1 location(s) · Florida International University · NCT05857969A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Partici
Phase 1 · 8 location(s) · AbbVie · NCT07306832Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumor
Phase 1 · 1 location(s) · University of Wisconsin, Madison · NCT02508038Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell
Phase 2 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT07256210A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activit
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT06191978HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Ste
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03326921Venetoclax to Augment Epigenetic Modification and Chemotherapy
Phase 1 · 1 location(s) · Medical College of Wisconsin · NCT05317403Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
Phase 1 · 9 location(s) · Norman J. Lacayo · NCT05101551Vyxeos® With Clofarabine for Pediatric AML
Phase 1 · 13 location(s) · Princess Maxima Center for Pediatric Oncology · NCT07156435PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
Phase 1 · 1 location(s) · Seattle Children's Hospital · NCT05105152Niclosamide in Pediatric Patients With Relapsed and Refractory AML
Phase 1 · 1 location(s) · Stanford University · NCT05188170Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute
Phase 1 · 10 location(s) · St. Jude Children's Research Hospital · NCT06177067
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.